Jaguar Health Showcases Gelclair at Oncology Nursing Society Congress

Jaguar Health, through its affiliate Napo Pharmaceuticals, is participating in the 50th Oncology Nursing Society Congress in Denver. This highlights their commitment to promoting Gelclair, an FDA-approved product for oral mucositis, commonly occurring in cancer patients.

Gelclair is engineered to manage and alleviate pain without numbing or burning the mouth's mucosal surface. The product targets head and neck cancer patients, bone marrow transplant patients, and healthcare professionals focused on oncology. These individuals are profoundly affected by oral mucositis, a prevalent and significant adverse effect in oncology.

Napo's efforts at the congress aim to raise awareness about Gelclair's benefits in supportive cancer care, aligning with Jaguar Health's broader mission to improve patients' quality of life by effectively managing complex side effects from cancer therapies.